Nicoletta Loggia
Technik-/Wissenschafts-/F&E-Leiter bei ORCHARD THERAPEUTICS PLC
Vermögen: - $ am 30.04.2024
Aktive Positionen von Nicoletta Loggia
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ORCHARD THERAPEUTICS PLC | Technik-/Wissenschafts-/F&E-Leiter | 09.09.2021 | - |
CANDEL THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 07.06.2023 | - |
Independent Dir/Board Member | 07.06.2023 | - |
Karriereverlauf von Nicoletta Loggia
Ausbildung von Nicoletta Loggia
University of Pavia | Doctorate Degree |
Statistik
International
Vereinigtes Königreich | 2 |
Italien | 2 |
Vereinigte Staaten | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 1 |
Doctorate Degree | 1 |
Director/Board Member | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
CANDEL THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Orchard Therapeutics Plc
Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Börse
- Insiders
- Nicoletta Loggia
- Erfahrung